Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Krystal Biotech, Inc.    KRYS

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners

share with twitter share with LinkedIn share with facebook
share via e-mail
08/16/2018 | 07:17pm EST

PITTSBURGH, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at $16 per share. The private placement will yield gross proceeds of $10 million and is expected to close on August 17, 2018, subject to the satisfaction of customary closing conditions.

“We are extremely pleased that an impressive investor like Frazier Healthcare Partners supports our efforts to become a leader in the field of dermatological diseases,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech, Inc.

Net proceeds from this offering are expected to be used to continue funding the research and development of Krystal’s pipeline product candidates.

Chardan acted as the sole placement agent in the transaction.

The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com.

Forward-Looking Statements
This press release contains forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements.  Although Krystal's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Krystal, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among others: actions by the FDA and other regulatory agencies, results and timing of current and planned clinical trials, risks related to the commercialization of our products, our ability to manufacture sufficient quantities of products for clinical trials and commercial launch, and those other risks detailed from time to time under the caption “Risk Factors” and elsewhere in Krystal Biotech's Securities and Exchange Commission (SEC) filings included in our Annual Report on Form on Form 10-K for the year ended December 31, 2017, and in future filings and reports of Krystal Biotech. The Company undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.

INVESTOR CONTACT
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com

MEDIA CONTACT
Darren Opland
LifeSci Public Relations
darren@lifescipublicrelations.com

Source: Krystal Biotech, Inc.

 

Primary Logo


© GlobeNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on KRYSTAL BIOTECH, INC.
01/24KRYSTAL BIOTECH : Summary ToggleKrystal Biotech Breaks Ground On Second Commerci..
PU
01/24Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing..
GL
01/21Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer
GL
2019Pfizer, Novartis lead $2 billion spending spree on gene therapy production
RE
2019Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Confer..
GL
2019KRYSTAL BIOTECH : Results of Operations and Financial Condition, Financial State..
AQ
2019KRYSTAL BIOTECH : Summary ToggleKrystal Biotech Reports Third Quarter 2019 Finan..
PU
2019KRYSTAL BIOTECH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
2019KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
2019Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results
GL
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -22,2 M
Net income 2019 -19,9 M
Finance 2019 187 M
Yield 2019 -
P/E ratio 2019 -53,1x
P/E ratio 2020 -29,5x
EV / Sales2019 infx
EV / Sales2020 infx
Capitalization 1 114 M
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 71,80  $
Last Close Price 64,35  $
Spread / Highest target 39,9%
Spread / Average Target 11,6%
Spread / Lowest Target -8,31%
EPS Revisions
Managers
NameTitle
Krish S. Krishnan Chairman, President & Chief Executive Officer
Suma M. Krishnan Chief Operating Officer & Director
Anthony A. Riley Chief Financial Officer
Schuyler Vinzant Senior Director-Regulatory & Clinical Operations
Dan S. Janney Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KRYSTAL BIOTECH, INC.16.20%1 114
GILEAD SCIENCES3.97%85 473
VERTEX PHARMACEUTICALS11.36%63 215
REGENERON PHARMACEUTICALS6.41%43 494
WUXI APPTEC CO., LTD.19.14%25 835
GENMAB10.23%15 420